A Subretinal Cell Delivery Method via Suprachoroidal Access in Minipigs: Safety and Surgical Outcomes
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Purpose: This study evaluated a new subretinal method for delivery of human or pig umbilical tissue-derived cells (hUTC or pUTC, respectively) using a novel subretinal injection cannula and suprachoroidal approach in Göttingen minipig eyes. hUTC (palucorcel) are currently under development for treating geographic atrophy in humans. Methods: Twenty-four Göttingen minipigs (divided into eight groups) were subretinally administered palucorcel, pUTC, or vehicle. In some cases, fluorescently labeled cells and vehicle were administered. Conjunctival cutdown and sclerotomy were performed, then a flexible cannula containing a microneedle was inserted and advanced into the suprachoroidal space. The microneedle was deployed and visualized; 50 μL cells (target concentration, 11.2 × 106 cells/mL [560,000 cells/eye]) or vehicle was injected subretinally. Safety outcomes were evaluated. Results: For all animals, cells and vehicle were successfully administered. Labeled cells or fluorescent vehicle were contained in the subretinal bleb, without leakage into the vitreous. No retinal detachment or vitreous traction band was identified by ophthalmologic examination. At all time points, observed microscopic changes were attributable to experimental procedures. On histopathology immediately after injection, localized retinal detachments were seen, along with focal retinal, choroidal, and/or scleral discontinuities. A moderate inflammatory response was seen in a limited number of animals. In the allogeneic setting, no antibody responses were detectable. Anti-human UTC antibodies were detected in the xenogeneic setting. Conclusions: Palucorcel, pUTC, and vehicle were successfully administered to Göttingen minipigs using a novel subretinal injection cannula via a suprachoroidal surgical approach, with no significant adverse events; therefore, this technique appears to be feasible for further clinical development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an experimental model of xenogeneic cells, transfected transchoroidally, granuloma formation was observed (though not with allogeneic cells) (33).”
From Subretinal therapy: technological solutions to surgical and immunological challenges (2022) · cites this paper as [33]
In the citing paper
“When breached, there is usually retraction of the underlying choroidal tissue leading to the formation of a small white round hole (20, 33).”
From Subretinal therapy: technological solutions to surgical and immunological challenges (2022) · cites this paper as [33]
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
The Role of Oxidative Stress in the Pathogenesis of Age-Related Macular Degeneration
Beatty, S., Koh, H.-H., Phil, M., Henson, D., & Boulton, M. (2000) · Survey of Ophthalmology · doi:10.1016/s0039-6257(00)00140-5 · Cited by 2,051 · cited 2×
“Initially, both stages are associated with minimal impairment of visual acuity.(3,8,9)”
BackgroundAge-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959
Ocular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807 · cited 1×
“While delivery of the cell product to the suprachoroidal space would be surgically easier, the subretinal space is an immune privilege site compared with all spaces beyond the RPE, which are not.(33) Cell survival would be decreased with delivery to the suprachoroidal space, and the possibility of retreatment if neede…”
BackgroundFifteen-Year Cumulative Incidence of Age-Related Macular Degeneration
Klein, R., Klein, B. E. K., Knudtson, M. D., Meuer, S. M., Swift, M., & Gangnon, R. E. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.10.040 · Cited by 638 · cited 1×
“developing GA is found in eyes with multiple large drusen (>125 lm) and in those with soft indistinct drusen, particularly when associated with macular pigmentary abnormalities.(12,14)”
BackgroundRisk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
Holz, F. G., Strauss, E. C., Schmitz-Valckenberg, S., & van Lookeren Campagne, M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.023 · Cited by 402 · cited 1×
“Initially, both stages are associated with minimal impairment of visual acuity.(3,8,9)”
BackgroundChoriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration
Biesemeier, A., Taubitz, T., Julien, S., Yoeruek, E., & Schraermeyer, U. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.003 · Cited by 287
Change in Area of Geographic Atrophy in the Age-Related Eye Disease Study: AREDS Report Number 26
(2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.198 · Cited by 276
Lund, R. D., Wang, S., Lu, B., Girman, S., Holmes, T., Sauvé, Y., Messina, D. J., Harris, I. R., Kihm, A. J., Harmon, A. M., et al. (2009) · STEM CELLS · doi:10.1634/stemcells.2006-0308 · Cited by 258 · cited 3×
“Palucorcel was derived from umbilical cord tissue of a single donor as described previously.(17,18) Palucorcel was developed in compliance with all relevant regulations, including donor consent.”
BackgroundMethod
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Long-acting microneedle formulations
Vora, L. K., Sabri, A. H., Naser, Y., Himawan, A., Hutton, A. R. J., Anjani, Q. K., Volpe-Zanutto, F., Mishra, D., Li, M., Rodgers, A. M., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115055 · Cited by 166
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
Subretinal therapy: technological solutions to surgical and immunological challenges
Ladha, R., Caspers, L. E., Willermain, F., & de Smet, M. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.846782 · Cited by 54
Heier, J. S., Ho, A. C., Samuel, M. A., Chang, T., Riemann, C. D., Kitchens, J. W., Slakter, J. S., Leiderman, Y. I., Spencer, R., Williams, G. A., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2019.11.011 · Cited by 41
Self-citationOcular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
A New Generation of Gene Therapies as the Future of Wet AMD Treatment
Błasiak, J., Pawłowska, E., Ciupińska, J., Derwich, M., Szczepańska, J., & Kaarniranta, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042386 · Cited by 33
“The main problems to solve are the delivery route and sustained expression of the VEGFA antagonist. gene therapy exposure to the vitreous and anterior segments, and compartmentalized delivery of the AAV vector as observed in preclinical studies [48–50].”
ResultRaimondi, R., Zollet, P., Rosa, F. P. D., Tsoutsanis, P., Stravalaci, M., Paulis, M., Inforzato, A., & Romano, M. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020682 · Cited by 26
Creating an Ocular Biofactory: Surgical Approaches in Gene Therapy for Acquired Retinal Diseases
Xu, D. N., Khan, M., & Ho, A. C. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000362 · Cited by 19
“Subretinal delivery of the cell suspension adjacent to areas of GA in nonneovascular AMD met safety and tolerability endpoints in a phase 1/2 clinical trial.(32,33)”
BackgroundHistomorphometric evaluation of the Göttingen minipig eye
Shrader, S. M., & Mowry, R. N. (2019) · Veterinary Ophthalmology · doi:10.1111/vop.12665 · Cited by 12
Genetic engineering and the eye
Murphy, R., & Martin, K. R. G. (2024) · Eye · doi:10.1038/s41433-024-03441-2 · Cited by 9
Development of a novel SupraChoroidal-to-Optic-NervE (SCONE) drug delivery system
Chiang, B., Heng, K., Jang, K., Dalal, R., Liao, Y. J., Myung, D. J., & Goldberg, J. L. (2024) · Drug Delivery · doi:10.1080/10717544.2024.2379369 · Cited by 6
“…et al., 2012; Rizzo et al., 2012; Olsen et al., 2011), and more recently the subretinal space for inherited retinal disorders (Davis et al., 2019;de smet et al., 2018). since the suprachoroidal space is a potential space bound by the sclera and choroid with limited thickness (chiang et al.,…”
BackgroundOcular Injection Techniques for Retinitis Pigmentosa: Intravitreal, Subretinal, and Suprachoroidal
Scherbakova, I., Ragi, S. D., & Sharma, T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2651-1_34 · Cited by 7
Gene Therapy in Age-related Macular Degeneration
Zhou, H. W., & Kim, L. A. (2025) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000567 · Cited by 4
Trockene AMD – zelluläre und gentherapeutische Behandlungsansätze
Johnen, S., & Koutsonas, A. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0898-4030 · Cited by 4
“De Smet et al. präsentierten im Jahr 2017 ein neues Injektionssystem, das bei einer weiteren geplanten multizentrischen Phase-II-Sicherheitsstudie getestet werden soll (NCT02659098) [30].”
BackgroundInfluentialKwok, J., Gray, A. P., Sato, Y., Savina, S., Dolgova, N., Sudharsan, R., Boye, S. L., Boye, S. L., Reichenbacker, S., Meyer, T., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01929-2 · Cited by 3
“The Orbit ® SDS device was initially developed for cell therapy delivery [18, 19], and has been recently used in a Phase I/II clinical trial (NCT03846193) aimed at evaluating the safety, dose response, and efficacy of an AAV-based gene therapy product (GT005) that encodes for a human complement…”
Olsen, T. W. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23605 · Cited by 1
Felder, A. E., Leiderman, Y. I., Tomback, M., Chicano, A., Burek, M., Arendovich, X., Wilkens, K., Frisbie, C., Luciano, C., Kanu, L. N., et al. (2020) · Journal of Medical Engineering & Technology · doi:10.1080/03091902.2020.1831632 · Cited by 1
Administration of Ocular Gene Therapy
Xu, D. N., Khan, M., Klufas, M. A., & Ho, A. C. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000365 · Cited by 1
Suprachoroidal Delivery of Subretinal Gene and Cell Therapy
Xu, D. N., Ma, K., & Ho, A. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-76853-9_9 · Cited by 1
Kadkhodaeian, H. A., Salati, A., Sameni, H., & Lashay, A. (2021) · Scientific Journal of Kurdistan University of Medical Sciences · doi:10.52547/sjku.26.4.105
Gene therapy for wet AMD: a paradigm shift in the standard of care
Asanad, S., & Boyer, D. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2026.2651330
“Current research is advancing Adeno-associated viral (AAV) serotypes to refine retinal pigment epithelium targeting, optimizing promoter systems for precise protein regulation, and exploring dual-pathway inhibition to prolong therapeutic effects [4,5].”
Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration
Musheyev, B., Kellner, R., Bouaziz, M., & Lieberman, R. M. (2026) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2026.04.001
Ladha, R., Caspers, L. E., Willermain, F., & de Smet, M. D. (2022) · doi:10.3389/fmed.2022.846782.s001
Metadata
- Authors
- de Smet, M. D., Lynch, J. L., Dejneka, N. S., Keane, M., & Khan, I. J.
- Affiliations
- MicroInvasive Ocular Surgery (MIOS) Center, Lausanne, Switzerland
- Janssen Research & Development (United States) (US)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2018-01-24
- Volume
- 59
- Issue
- 1
- Pages
- 311
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2783918548
- Cited by
- 23
- References
- 39
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 1
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- suprachoroidal injection, Göttingen minipig, microneedles, geographic atrophy, retinal detachment, allogeneic transplantation, cell therapy safety
- MeSH terms
- Animals, Choroid, Extracellular Space, Macular Degeneration, Male, Swine, Swine, Miniature, Umbilical Cord, Geographic Atrophy, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.